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INTRODUCTION
Suboptimal medication refill adherence among individuals with chronic conditions is a significant clinical problem and has been described as a risk factor for adverse health outcomes and for preventable medication-related morbidities and mortalities.
1 Adherence to prescribed medications is usually defined as the extent to which an individual acts in accordance with the prescribed dosing interval and dose of prescribed medications.
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Oversupply of prescribed medications leads to excessive amounts of medications available to patients and may cause their overuse with a potential risk of adverse drug reactions (ADRs).
Undersupply of prescribed medications may lead to their underuse and sub-therapeutic effects (STEs) of these medications.
Earlier studies on adherence conducted in clinical trials have focused on patients who were willing to participate in research studies and received a high attention from health providers.
However, the evidence on actual reported medication-related adverse outcomes due to refill non adherence to long-term medications in clinical practice is limited. 3 In numerous previous population-based studies, refill adherence has been assessed in prescription databases without investigating its association with the ADRs and STEs perceived by patients.
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To the best of our knowledge, no previous population study assessed the association between refill non adherence to long-term medications and self-reported ADRs and STEs from these medications in a representative sample of the general population. Such evidence is needed for improving the management and outcomes of medication therapies. The objectives of this study were therefore to assess the refill adherence for dispensed oral long-term medications in a random sample of the general adult population in Sweden, and to investigate whether the percentages of self-reported ADRs and STEs differed for medications with adequate refill adherence, oversupply and undersupply.
METHODS

Study population
A sample of 14 000 persons aged 18 years and above registered in Sweden on January 1 st 2010 was drawn by Statistic Sweden from the Total Population Register, using simple random sampling. 7 Persons who deceased or migrated between the sampling date and the date of administrating the survey were removed (n=69) and the survey was mailed to 13 921 individuals in October 2010.
This study included respondents who were dispensed two or more refills of oral antihypertensive, oral lipid-lowering or oral anti-diabetic medications during the study period.
These medications were selected as they are prescribed to a large proportion of the population, are available on prescription only, require long periods of adherent use to achieve the desired outcomes, and their adverse outcomes are well described in studies using clinical data. 1, 8, 9 Persons with multidose dispensed medications (ApoDos) were excluded, because information on the prescribed daily dose was missing. Non-interpretable dosage instructions such as "1-2 tablets daily", "2 tablets per day, decrease if side effects" or "1 tablet when needed" (as diuretics for treatment of swallowed legs) were also excluded ( Figure 1 ).
Data sources
The survey included open and closed questions on experienced ADRs and STEs during the past month, the associated medications and whether the adverse outcomes caused hospitalizations. The questionnaire was developed by the research group based on earlier studies, 10, 11 and was pilot-tested in different populations for face and content validity.
Medications reported to be responsible for ADRs or STEs by respondents were coded using Anatomical Therapeutic Chemical classification (ATC). 12 If a medication class was reported to be responsible for an ADR or STE, individual medications belonging to this class and dispensed to the respondent were considered responsible for the ADR or STE.
Survey responses and registers data were combined using the unique personal identity number. Data on dispensed prescription medications were obtained from the Swedish
Prescribed Drug Register (SPDR). 13 It contains information on the name of the dispensed medications, the ATC code, the amount of medications dispensed, the prescribed daily dose given in a free text field, and the date of dispensing.
The selected medication classes were defined as the following ATC-codes: i) A10B (oral antidiabetics); ii) C02, C03, C07, C08 and C09 (antihypertensives); iii) and C10 (lipid-lowering drugs). 12 Information about hospitalizations was retrieved from the National Patient Register, including the date of hospitalization and discharge. Sociodemographic characteristics were retrieved from the LISA database (the longitudinal integration database for health insurance and labour market studies) from Statistics Sweden.
Defining refill adherence
Refill adherence calculations were performed at the chemical substance level (5 th ATC level).
Dosage instructions given in free text fields were interpreted to determine the number of prescribed daily units. The refill adherence was measured using the continuous measure of medication acquisition (CMA). 14, 15 The CMA was assessed during a 10-month study period, which started ten months before the date of returning the survey and thus included the one month period for the eventual occurrence of an ADR or STE. Because long-term medications are usually dispensed every three months in Sweden, the 10-month period was sufficient to include the minimum of two refills for calculating the CMA.
The CMA was defined as the cumulative number of days' supply divided by the number of days during the 10-month study period. The number of days during the study period was calculated from the index date (first medication dispensing during the study period) until the end of the observation period.
CMA =
To gain the cumulative number of days' supply for each included dispensation, the number of dispensed units was divided by the number of prescribed daily units.
Calculations of refill adherence scenarios are illustrated in Figure 2 . If the last refill day exceeded the 10-month observation period, only the number of day's supply included during the observation period were included. If hospitalizations occurred during the study period, medications were assumed to be provided at hospital and the number of hospitalization days was added to the cumulative number of days' supply.
Number of days in the study period Number of days during the observation period period Cumulative number of days' supply We applied cut-offs used in previous studies for CMA. Adequate refill adherence to a medication therapy was defined as a CMA between 0.8 and 1.2, oversupply of medication as a CMA > 1.2 and undersupply of a medication as a CMA < 0.8. [16] [17] [18] A person was considered to have an adequate refill adherence if all the medication therapies belonging to the therapeutic class had adequate refill adherence. A person was considered to oversupply or to undersupply if at least one of the refilled medication therapies were oversupplied or undersupplied.
Statistical analysis
The study population was described by gender, age, hospitalizations during the study period, the mean number of dispensed medications, and which of the studied medications they were 
Ethical considerations
The respondents consented to participate to the study by responding to the survey. An introductory letter sent in conjunction with the survey followed the principals of the Declaration of Helsinki. 19 The sampled persons were informed that their answers would be complemented with data from population registers and that by responding the survey they also consented that registers information will be accessed and used. In order to protect the integrity of respondents, Statistics Sweden administered the survey, linked the survey responses to register data, and de-identified the combined dataset. An ethical approval was received from the Regional ethical review board in Gothenburg (registration number: 238-2010).
RESULTS
Of all respondents (n=7099), 30.1% was dispensed at least one studied medication. Among them, 3.1% had multi-dose dispensed drugs, 9.8% had only one refill during the study period, and 1.4% had non-interpretable dosage instructions, and were therefore excluded ( Figure 1 ).
Finally, 1827 persons were included in the study. The characteristics of the study population are presented in and 60% of persons who refilled oral anti-diabetics had an adequate refill adherence (Table   3 ).
In total, 107 ADRs and 52 STEs were reported representing respectively 2.6% and 1.3% of the studied medication therapies ( (Table 5) . No STEs and three ADRs were reported for CMA < 0.6.
DISCUSSION
In this study, adequate refill adherence was found in two thirds of the medication therapies.
More than half of persons who refilled antihypertensives and about two thirds of individuals who refilled lipid lowering drugs and oral anti-diabetics had adequate refill adherence to all their medications from theses therapeutic classes. Moreover, the percentages of self-reported ADRs and STEs did not differ for medications with adequate refill adherence, oversupply and undersupply.
The CMA rates found in this study were similar to those found in previous studies using the Swedish Prescribed Drug Register. 4, 20 High rates of CMA have also been described in other studies measuring refill adherence from prescription databases, but CMAs superior to one have usually been truncated to one. 5, 6 As we purposefully included oversupply as a pattern of refill non adherence, CMAs superior to one were not truncated to one in our study, increasing the median CMA in our study compared to some previous studies. 6 In previous studies, adherence rates have varied from 35% to 97% for antihypertensives, 21 from 37% to 80% for lipid-lowering drugs, 22 and from 36% to 93% for oral anti-diabetics. 23 Refill Adherence depends on factors such as the study population characteristics and the measurement method used. Although there is no gold standard method to measure the refill adherence using pharmacy claims databases, a previous review has found that CMA is a reliable measure. 24 To the best of our knowledge; our study is the first investigating the association between refill adherence to long-term medications and self-reporting of ADRs and STEs at the general population level. We did not find evidence of more ADRs when medications were oversupplied, which may be explained by the Swedish reimbursement system. Prescriptions can be refilled when two-thirds of the previous medication period has passed; 25 and the reimbursement increases during a calendar year with the accumulated co-payment which can provide incentives to stockpile and oversupplies, especially in individuals exempted from co-payment. However, we did not control for co-payment. A previous Swedish study has found that oversupply was a leading cause to return unused dispensed medications, 26 and that about half of returned packages were unused. 27 Even if oversupply may not lead to higher occurrence of ADRs, it remains a source of extra high costs and wastage for the health care. adherence using multivariable models with adjustment to the respondents' characteristics.
When interpreting this study some limitations should be considered. A response bias might have been present. Individuals with severe medical conditions might not have answered the survey. However, these individuals would require multidose dispensed medications; therefore their refill adherence would not be possible to calculate. Another limitation is that our study population mainly represents elderly, but this was expected due to the studied medications.
Similar to other refill adherence studies, medication consumption was assumed, and the timing of the doses of medication was unknown. Nevertheless, we used dispensing and not prescription data and the act of refilling a medication reflects a patient's active decision to continue with medication. 20 One strength of our study is that adherence was not self-reported as non-adherent individuals tend to describe their medication's intake behaviors inaccurately, which would blur any differences of adherence.
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Although we aimed to investigate whether the percentages of self-reported ADRs and STEs differed for medications with adequate refill adherence, oversupply and undersupply, respondents might have reported ADRs or STEs that occurred over the year and that could be the reason of their refill non adherence. However, because of the low number of reported ADRs and STEs, this was unlikely to change the refill adherence found in our study. It was not possible to verify whether individuals were prescribed the appropriate medications for their health conditions. Finally, the extent to which our findings are generalizable to all individuals taking the studied long-term medications is unknown. However, our study was comprehensive as the sample was drawn from the whole Swedish adult population. 
CONCLUSIONS
